HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

BACKGROUND: Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval of trastuzumab, targeted therapies are emerging as promising treatment options for the disease. This study aimed to explore the molecular segmentation of several known therapeutics targets, human epider...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liu, Y J, Shen, D, Yin, X, Gavine, P, Zhang, T, Su, X, Zhan, P, Xu, Y, Lv, J, Qian, J, Liu, C, Sun, Y, Qian, Z, Zhang, J, Gu, Y, Ni, X
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950883/
https://ncbi.nlm.nih.gov/pubmed/24518603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.61
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados